Trivago Tanks Following Updated Guidance
Trivago watched its shares get crushed on Wednesday after the company updated its full-year guidance.
All Work
Chris Lange
Sarepta Therapeutics Surges Following Duchenne Muscular Dystrophy Trial
Sarepta Therapeutics saw its shares make a handy gain on Wednesday after the firm announced muscle biopsy results from its mid-stage study for the treatment of Duchenne muscular dystrophy.
Rhythm Pharmaceuticals Files for IPO
Biopharmaceutical company Rhythm Pharmaceuticals has with the SEC regarding its initial public offering.
How Insmed Is Capitalizing on Its Huge Late-Stage Success
Insmed has filed with the SEC for a secondary offering. This follows a surge in the share price following positive late-stage results from its clinical study in the treatment of nontuberculous mycobacteria lung disease.
Hewlett Packard Enterprise Clears Low Bar for Q3
Hewlett Packard Enterprise Co. (NYSE: HPE) released its fiscal third-quarter financial results after the markets closed on Tuesday. The company said that it had $0.30 in earnings per share (EPS) and $8.2 billion in…
Tuesday’s Biggest Winners and Losers in the S&P 500
Tuesday was a down day for the U.S. broad markets, actually one of the worst trading days of the year. Despite this, crude oil managed to have one of its best days but not…
Why Merrill Lynch Is Growing Much More Bullish on US Steel Stocks
Rising input costs and a more bullish stance on China have created a bullish sentiment in steel stocks recently. One analyst has rasied its price targets on U.S. steel companies across the board.
Tilman Fertitta Buys Houston Rockets in Blockbuster Deal
After being on the market for nearly two months, the Houston Rockets have found a buyer for the franchise who will pay an unprecedented $2.2 billion.
FDA Crushes Cellectis With Clinical Hold
Cellectis shares tumbled early on Tuesday after the firm announced that a couple of its early-stage studies were put on hold by the FDA.
BioCryst Pharma Sees Brief Surge on Mid-Stage Trial Win
BioCryst Pharmaceuticals saw its shares make a handy gain on early Tuesday after it released the final results from its mid-stage clinical trial in hereditary angioedema.
Insmed More Than Doubles on Late-Stage Trial
Insmed saw its shares more than double early on Tuesday after the firm released late-stage results from its clinical study in the treatment of nontuberculous mycobacteria lung disease.
Lululemon Earnings Stretch to Another Win
Lululemon Athletica shares rose Friday in the wake of a better-than-expected fiscal second-quarter report late on Thursday.
How Palo Alto Crushed Q4 Earnings
Shares of Palo Alto Networks climbed handily after it reported better-than-expected fiscal fourth-quarter earnings results.
Even More Affected Accounts Found in Wells Fargo Scandal
Wells Fargo has announced the completion of its third-party review of retail banking accounts dating back to 2009. What reviewers found was more than what they bargained for.
FDA Crushes SteadyMed With Refusal to File Letter
SteadyMed shares plummeted after the firm had a setback from the FDA regarding its pulmonary arterial hypertension treatment.
US LBM Gears Up for IPO
Specialty building materials distributor US LBM has amended its filing with the SEC regarding its initial public offering.
Dollar General Q2 Earnings Beat Due to New Stores, Increased Traffic
Dollar General released better-than-expected fiscal second-quarter earnings report before the markets opened on Thursday.
August ADP Employment Report Beats Expectations
The ADP Employment Report was released Wednesday morning and handily topped Bloomberg expectations, which may help reset expectations for Friday's employment report from the Department of Labor.
Mazor Robotics Jumps After Medtronic Collaboration Update
Mazor Robotics saw its shares make a handy gain to kick off hump day after it was announced that the company has entered the next phase of its strategic partnership with Medtronic earlier than…
Why Otonomy Shares Are Getting Absolutely Crushed
Otonomy saw its shares crater after the firm announced results for its Averts-1 late-stage trial of Otividex in patients with Ménière’s disease.